<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053095_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133608</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>5</safetyreportversion>
		<safetyreportid>PHHY2010GR74124</safetyreportid>
		<primarysourcecountry>GR</primarysourcecountry>
		<occurcountry>GR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20121211</transmissiondate>
		<reporttype>2</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20101103</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20121128</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2010GR74124</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>H</reportergivename>
			<reporterfamilyname>Berdoussi</reporterfamilyname>
			<reporterorganization>AG Sophia Children's Hospital</reporterorganization>
			<reportercountry>GR</reportercountry>
			<qualification>1</qualification>
			<sponsorstudynumb>CICL670A2411</sponsorstudynumb>
			<observestudytype>2</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>STK</patientinitial>
			<patientinvestigationnumb>0005</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>20050424</patientbirthdate>
			<patientweight>17</patientweight>
			<patientheight>110</patientheight>
			<patientsex>2</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypercalciuria</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Thalassaemia</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Hypokalemia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hypokalemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypokalaemia</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20101030</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20101105</reactionenddate>
				<reactionduration>7</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>471</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Abdominal pain</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Abdominal pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Abdominal pain</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20101105</reactionenddate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Vomiting</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Vomiting</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Vomiting</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20101030</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20101105</reactionenddate>
				<reactionduration>7</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>471</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testname>Alanine aminotransferase increased</testname>
				<testresult>110</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Alanine aminotransferase increased</testname>
				<testresult>110</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20101102</testdate>
				<testname>Alanine aminotransferase increased</testname>
				<testresult>442</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20101102</testdate>
				<testname>Alanine aminotransferase increased</testname>
				<testresult>442</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Aspartate aminotransferase</testname>
				<testresult>26</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Aspartate aminotransferase</testname>
				<testresult>26</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Blood calcium</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood chloride</testname>
				<testresult>105 mEq/L</testresult>
				<testunit>mg/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood chloride</testname>
				<testresult>105 mEq/L</testresult>
				<testunit>mg/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood creatinine</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood phosphorus</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20101102</testdate>
				<testname>Blood phosphorus</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood potassium</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20101102</testdate>
				<testname>Blood potassium</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood sodium</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood urea</testname>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ICL670A </medicinalproduct>
				<obtaindrugcountry>GR</obtaindrugcountry>
				<drugauthorizationnumb>21-882</drugauthorizationnumb>
				<drugauthorizationcountry>GR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>625</drugstructuredosagenumb>
				<drugstructuredosageunit>007</drugstructuredosageunit>
				<drugdosagetext>625 mg/kg, daily</drugdosagetext>
				<drugdosageform>Dispersible Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Thalassaemia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20090717</drugstartdate>
				<drugstartperiod>471</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>1</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20101030</drugenddate>
				<drugtreatmentduration>471</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>*CGP 72670*</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal pain</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal pain</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypokalaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypokalaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Vomiting</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Vomiting</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ICL670A </medicinalproduct>
				<obtaindrugcountry>GR</obtaindrugcountry>
				<drugauthorizationnumb>21-882</drugauthorizationnumb>
				<drugauthorizationcountry>GR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosageform>Dispersible Tablet</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Iron overload</drugindication>
				<drugstartperiod>471</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>1</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>*CGP 72670*</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal pain</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal pain</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypokalaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypokalaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Vomiting</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Vomiting</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>DIURENE</medicinalproduct>
				<obtaindrugcountry>GR</obtaindrugcountry>
				<drugauthorizationcountry>GR</drugauthorizationcountry>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugdosagetext>0.5 DF, daily</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypercalciuria</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20100608</drugstartdate>
				<drugstartperiod>145</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>1</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20101030</drugenddate>
				<drugtreatmentduration>145</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMILORIDE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Initial post-marketing study report received from an investigator on 03 Nov 2010: This patient had a medical history of thalassemia. The patient was on treatment with Exjade (deferasirox) for transfusion iron overload from 17 Jul 2009 to 30 Oct 2010 at a dose of 625mg (37mg/kg daily). The patient had developed abdominal pain and vomiting. The patient also concomitantly took Diuren for hypercalciuria from 08 Jun 2010 to 30 Oct 2010. Exjade and Diuren were discontinued on the same date. The patient was examined on 02 Nov 2010 and was found to be weak and with diffuse abdominal tenderness especially on right upper quadrant. On 02 Nov 2010, laboratory evaluation has found the patient to have hypokalemia and transaminasaemia. The lab data was ALT of 442 U/L, potassium of 2mmol/L and phosphorus of 1.4 mg/dL. The patient was hospitalized for IV hydration. The physician assessed that the event hypokalemia can also be caused by Diuren. The outcome of the event was reported to be improving by the physician. The physician assessed the causality for all events to be suspected.

Follow-up information received from an investigator on 15 Nov 2010: The patient had remained in the hospital. The patient was still taking IV hydration therapy and electrolyte supplementation. The patient had recovered slowly and after three days her laboratory tests were SGPT=110U/L(high) and P=2.0mg/dl(low),. On 05 Nov 2010, the patient had completely recovered. Exjade may have caused for renal dysfunction.  All the events reported were suspected to Exjade and there was a possibility that Diuren also contributed to the events. No more information was available.

Follow-up report received from a physician on 22 Nov 2010: The patient (patient ID: 0005 and centre ID: 702) received Exjade for transfusion iron overload secondary to thalassemia. The patient had taken an exit ticket from the hospital at the time of report. The therapies of Exjade (deferasirox) and Diuren had been stopped since 30 Oct 2010. The patient has been withdrawn from study. The outcome of vomiting, abdominal pain and hypokalemia was reported as completely recovered on 05 Nov 2010.

Follow up report received on 27 Nov 2012: During hospitalization the patient (patient number: 0005 and center number: 702) was diagnosed with renal dysfunction, weak, diffuse abdominal tenderness especially on right upper quadrant, transaminasemia events and  these events were assessed as non-serious. The event experienced hypokalemia was assessed as non-serious and consequence of severe vomiting.

Follow up report received on 28 Nov 2012: The investigator reported that renal dysfunction, weak, diffuse abdominal tenderness especially on right upper quadrant and transaminasemia were not serious adverse events but the finding during hospitalization. Added patient details and causality was updated as not suspected to the treatment with Exjade.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
